Drug CostMay 19, 2026·7 min read·By Jacob Posner, Founder & Editor
What Does Imbruvica Cost in 2026 After Medicare Price Negotiations?
The IRA brought ibrutinib's Medicare Maximum Fair Price to $9,319 per month starting January 2026, down from a list price near $14,934. Without insurance, the retail cash price runs $14,000 to $18,000 per month. Here is what Medicare Part D, patient assistance programs, and the 2026 $2,100 OOP cap mean for CLL and MCL patients paying for Imbruvica.
Quick Answer: As of 2026, the Medicare Maximum Fair Price for ibrutinib (Imbruvica) is $9,319 per 30-day supply under the Inflation Reduction Act negotiation, a 38% reduction from the previous list price of $14,934. Without insurance, retail cash prices run $14,000 to $18,000 per month. Medicare Part D patients are protected by the $2,100 annual OOP cap in 2026. AbbVie's Imbruvica By Your Side program provides free drug to qualifying uninsured patients and copay assistance ($0 possible) for commercially insured patients.
Ibrutinib (Imbruvica) is an oral targeted therapy for blood cancers including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and Waldenstrom macroglobulinemia. It was among the first drugs approved by FDA under the breakthrough therapy designation, and it became one of the highest-revenue cancer drugs in the US. Its annual list price exceeded $178,000 per year before IRA negotiations.
Because ibrutinib is an oral drug dispensed through specialty pharmacies, it is billed under Medicare Part D, not Part B. This means there is no J-code for ibrutinib, and it does not go through the ASP (Average Sales Price) system used for infused or injected cancer drugs. Instead, pricing flows through the Part D plan, subject to the 2026 IRA Maximum Fair Price of $9,319 per month and the $2,100 annual OOP cap.
For patients without Medicare, the retail cash price for ibrutinib runs $14,000 to $18,000 per 30-day supply. AbbVie's Imbruvica By Your Side program, together with foundations including the Leukemia and Lymphoma Society and the PAN Foundation, provides financial assistance pathways for patients who cannot afford this cost. Check your eligibility at the AbbVie Access portal before assuming you have to pay full price.
What Imbruvica Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same imbruvica can cost many times more at a hospital than at your local pharmacy:
2026 Imbruvica Price by Point of Pay
Where you pay
Typical cost
Notes
Specialty pharmacy (retail cash)
$14,000 - $18,000/month
Cash price without insurance or copay assistance
Medicare Part D (2026 IRA Maximum Fair Price)
$9,319/month (MFP); max $2,100/year OOP
IRA negotiated price, effective Jan 1, 2026. OOP capped at $2,100/year.
Inpatient hospital (if dispensed during admission)
$15,000 - $20,000/month
Hospital facility rate markup on oral oncology agents
Commercial insurance with copay card
$0/month possible
Imbruvica By Your Side copay card for commercially insured patients
Medicaid
$1 - $4/prescription
Standard Medicaid copay; coverage requires prior authorization in most states
IRA Maximum Fair Price of $9,319/month effective January 1, 2026 per CMS. Retail cash prices sourced from GoodRx and PharmacyChecker. Inpatient facility rates reflect hospital markup practices for specialty oral oncology agents.
Source: CMS Medicare Drug Price Negotiation Program 2026, GoodRx, PharmacyChecker
Why Hospitals Charge So Much
Ibrutinib is an oral specialty oncology drug, which means hospitals that dispense it during an inpatient stay mark it up as part of their facility charge rather than billing it through a Medicare Part B J-code. The hospital acquires the drug from a specialty distributor, adds a facility markup for pharmacy overhead, dispensing, and oncology support services, and charges the resulting total against the patient's inpatient admission.
Because ibrutinib has no published Medicare ASP rate (it is a Part D drug, not a Part B drug), there is no single government benchmark to compare against hospital billing. This makes inpatient ibrutinib charges harder to dispute than injected cancer drugs that have public ASP rates. Patients receiving ibrutinib as part of an inpatient admission should request an itemized bill and verify that the charge per capsule aligns with the drug's known specialty pharmacy price, not a facility-inflated rate.
The 2026 Part D IRA Maximum Fair Price of $9,319 per 30-day supply applies to Medicare Part D outpatient prescriptions, not inpatient hospital billing. If ibrutinib appears on an inpatient bill at a charge well above the known specialty pharmacy acquisition cost, that is a candidate for dispute. Contact the hospital's patient financial services department and ask for a line-item breakdown of the drug charge versus the dispensing and administration fees.
Lower your hospital bill. Or get it forgiven.
Free in 30 seconds. We check every charge for errors and overcharges, see if you qualify for free care at your hospital, and write a custom dispute letter ready to send. Most patients save hundreds.
AbbVie (the manufacturer) and several independent foundations offer financial assistance programs for patients who cannot afford ibrutinib. For commercially insured patients, the copay card can reduce cost to $0 per month. For uninsured or Medicare patients, direct PAP and foundation grants are available:
Patient assistance programs for Imbruvica
Manufacturer program
Cost / Benefit
How to apply
Imbruvica By Your Side (AbbVie PAP)
Free ibrutinib for qualifying uninsured or underinsured patients
abbvieaccess.com/brand/imbruvica
Imbruvica By Your Side Copay Card
$0/month possible for commercially insured patients
Up to $10,000/year for qualifying blood cancer patients
lls.org/support-resources/financial-support
PAN Foundation (Patient Advocate Network)
Grants for Medicare and underinsured patients with blood cancers
panfoundation.org
Eligibility for manufacturer PAP typically requires income documentation and proof of insurance status. Copay card is not valid for Medicare or Medicaid patients. Foundation grants have separate eligibility criteria and may have limited funding windows.
Ibrutinib is covered under Medicare Part D as a specialty oral oncology drug. Starting January 1, 2026, Medicare Part D enrollees benefit from the IRA-negotiated Maximum Fair Price of $9,319 per 30-day supply. More importantly, the 2026 Part D annual out-of-pocket cap of $2,100 means that once you have spent $2,100 on all covered Part D drugs in the calendar year, you pay $0 for the remainder of the year. For a drug with monthly costs in the thousands, most patients will hit the $2,100 OOP cap early in the year.
The Low Income Subsidy (Extra Help) program is also relevant for lower-income Medicare patients. If you qualify for Extra Help, your Part D cost-sharing for ibrutinib can be reduced to a nominal copay of $0 to $11.20 per prescription in 2026. To check eligibility, visit SSA.gov or call 1-800-MEDICARE. Patients with income below 150% FPL should apply before assuming full Part D cost.
Common Imbruvica Billing Errors
Ibrutinib billing is complex because it is an oral specialty drug that flows through Part D, not Part B. Watch for these billing errors if you are disputing an ibrutinib charge:
Drug billed through Part B (as an infusion or injection) instead of Part D, resulting in incorrect patient cost-sharing
Dose billed does not match prescribed dose (e.g., 560 mg/day billed when 420 mg/day was prescribed)
Specialty pharmacy bills a 90-day supply when a 30-day supply was dispensed
Copay card not applied despite patient enrollment, resulting in patient being billed commercial plan cost-sharing
Inpatient hospital charges ibrutinib separately from the DRG (Diagnosis Related Group) bundled payment, creating a double-billing situation
Post-IRA billing at pre-negotiation list price ($14,934) instead of the 2026 Maximum Fair Price ($9,319) for Part D claims
Frequently Asked Questions
What is the 2026 Medicare price for Imbruvica?
The 2026 Medicare Maximum Fair Price (MFP) for ibrutinib (Imbruvica) is $9,319 per 30-day supply, set under the Inflation Reduction Act price negotiation. This is 38% lower than the pre-negotiation list price of $14,934. This MFP applies to Medicare Part D prescriptions effective January 1, 2026. Medicare Part D enrollees are also protected by the 2026 annual out-of-pocket cap of $2,100, meaning most ibrutinib patients will pay at most $2,100 total for all Part D drugs in 2026.
Is Imbruvica covered under Medicare Part B or Part D?
Imbruvica (ibrutinib) is an oral drug dispensed through specialty pharmacies. It is covered under Medicare Part D, not Part B. Part B covers drugs that are typically administered in a clinical setting by injection or infusion and billed with a J-code. Ibrutinib has no J-code. If you have Medicare, you fill ibrutinib through a Part D prescription drug plan at a specialty pharmacy.
What does ibrutinib cost without insurance in 2026?
Without insurance or patient assistance, ibrutinib (Imbruvica) retails for $14,000 to $18,000 per month at US specialty pharmacies. The exact price depends on the dose: the standard 420 mg daily dose for CLL runs approximately $14,000 to $15,000 per 30-day supply. AbbVie's Imbruvica By Your Side program can reduce this to $0 for qualifying uninsured patients. Foundation grants from the Leukemia and Lymphoma Society and PAN Foundation also cover gaps.
How does the Imbruvica By Your Side program work?
The Imbruvica By Your Side program is AbbVie's patient support initiative with two components. For commercially insured patients, a copay card can reduce monthly out-of-pocket cost to $0. For uninsured or underinsured patients who meet income criteria, a Patient Assistance Program provides free ibrutinib. Apply through abbvieaccess.com or call 1-888-968-7743. The program is not available to Medicare or Medicaid patients, but those patients may qualify for foundation assistance from LLS or PAN Foundation.
What is the Inflation Reduction Act negotiated price for Imbruvica?
The Inflation Reduction Act of 2022 authorized Medicare to negotiate drug prices directly for the first time. Imbruvica (ibrutinib) was one of the first 10 drugs selected for negotiation. The resulting Maximum Fair Price is $9,319 per 30-day supply, effective January 1, 2026, representing a 38% reduction from the 2023 list price of $14,934. CMS estimates the negotiation will save Medicare beneficiaries an aggregate $1.5 billion in 2026.
Does Medicaid cover Imbruvica?
Yes, Medicaid covers ibrutinib (Imbruvica) in all states, though most require prior authorization given the drug's specialty oncology status and high cost. Standard Medicaid copays are $1 to $4 per prescription. Medicaid patients typically pay far less for ibrutinib than commercially insured or cash-pay patients. If you have low income and are not yet enrolled in Medicaid, check your eligibility at coveredusa.org or your state Medicaid agency.
What are common billing errors for ibrutinib?
The most common billing errors for ibrutinib include: the drug billed under Part B (with a J-code) instead of Part D; doses billed that do not match the prescribed dose; specialty pharmacy billing a 90-day supply when 30 days were dispensed; the copay card not applied despite patient enrollment; and post-IRA billing at the pre-negotiation list price of $14,934 instead of the 2026 Maximum Fair Price of $9,319. If any of these apply, contact your insurer or the specialty pharmacy to request a corrected claim.
Which cancers does Imbruvica treat?
Imbruvica (ibrutinib) is FDA-approved for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD). It works by blocking Bruton's tyrosine kinase (BTK), a protein critical to the survival and proliferation of malignant B-cells. Most patients take it as a daily oral capsule or tablet at doses ranging from 280 mg to 560 mg depending on the indication.
Lower your hospital bill. Or get it forgiven.
Free in 30 seconds. We check every charge for errors and overcharges, see if you qualify for free care at your hospital, and write a custom dispute letter ready to send. Most patients save hundreds.
